Psoriasis in Skin of Color Unplugged: Addressing the Barriers to Patient Care and Relief

Various gaps in the management of psoriasis patients with skin of color (SOC) persist due to a lack of training on SOC and inherent barriers to care. As a result, psoriasis patients with SOC are often misdiagnosed, experience more severe disease, and experience more disease burden. Recent clinical trial data supports the need for nuanced care when treating psoriasis patients with SOC using systemic agents. It is important that clinicians are able to identify treatment barriers and develop strategies to address these barriers and personalize care.

In collaboration with the Skin of Color Society and the National Psoriasis Foundation, this educational initiative will focus on the clinical presentation, disease burden, clinical and therapeutic nuances of treatment, and strategies to address barriers to care and individualize treatment plans.

Target Audience

This activity is designed for an audience of physicians, nurses, and other advanced practice providers (nurse practitioners/physician assistants) in medical practices that specialize in dermatology.

Learning Objectives

Upon completion of the educational activity, participants should be better able to:

  • Address the barriers to diagnosing psoriasis in patients with SOC.
  • Discuss the impact and burden of psoriatic disease for patients with SOC.
  • Summarize updates in the treatment of psoriasis, including nuances of treatment of SOC patients.
  • Implement strategies to address patients’ barriers to care and build patient-centered treatment plans.
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 ANCC
  • 1.00 Participation
Course opens: 
Course expires: 
  • Opening Remarks
  • Case #1
  • Case #2
  • Case #3
  • Case #4
  • Closing Remarks

Amy McMichael, MD (Chair)
Professor and Chair of Dermatology and Dermatology 
Residency Director at the Wake Forest University School of Medicine
Winston-Salem, NC

April Armstrong, MD, MPH
Professor and Chief of Dermatology at University of California
Los Angeles, CA


Eingun James Song, MD, FAAD
Co-Chief Medical Officer, Director of Clinical Research at Frontier Dermatology
Seattle, WA



This activity is provided by AKH Inc., Advancing Knowledge in Healthcare and Tarsus Cardio dba LiVDerm.

Advancing Knowledge in Healthcare Inc.LiVDerm logo

Joint Accredited Provider Logo In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Tarsus Cardio dba LiVDerm. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


AKH Inc., Advancing Knowledge in Healthcare designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


1 ANCC contact hour.

Commercial Support

This activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.


It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.




Commercial Interest

April Armstrong, MD, MPH


Almirall, Arcutis, ASLAN, Beiersdorf, BMS, Dermavant, Lilly, Galderma, Incyte, Janssen, LEO, Modernizing Medicine, Nimbus, Novartis, Ortho Derm, Pfizer, Regeneron, Sanofi, Sun Pharma, UCB


Abbvie, ASLAN, BMS, Dermavant, Lilly, Galderma, Incyte, Janssen, LEO, Nimbus, Novartis, Ortho Derm, Pfizer, Sanofi, UCB


Abbvie, BMS, Regeneron, Sanofi, UCB



Amy McMichael, MD


Abbvie, Arcutis, Bristol Myers Squibb, Concert Pharmaceuticals, Eli Lilly, eResearch Technology Inc, Galderma Incyte, Janssen, Johnson & Johnson, L'Oreal, Pfizer, Proctor & Gamble, Revian, Samumed, Sanofi Regeneron, Sun Pharmaceuticals, UCB

Royalties or patent beneficiary

Informa Healthcare, UpToDate

Eingun James Song, MD, FAAD


Abbvie, Alphyn, Amgen, Arcutis, BMS, Boehringer Ingeheim, Dermavant, Eli Lilly, Incyte, Janssen, LEO, Novartis, Ortho-dermatologics, Pfizer, Sanofi & Regeneron, SUN, UCD


AbbVie, Amgen, Arcutis, BMS, Dermavant, Incyte, Janssen, Sanofi & Regeneron, SUN


AbbVie, Amgen, Arcutis, BMS, Dermavant, Eli Lilly, Incyte, Janssen, Novartis, Ortho-dermatologics, Pfizer, Sanofi & Regeneron, SUN, UCB

Dorothy Caputo, MA, BSN, RN, VP, Healthcare CE and Operations


Nothing to disclose

Michele Bielarski, RN (planner/reviewer)


Nothing to disclose

AKH Inc Staff and Planners


Nothing to disclose

Tarsus dba LiVDerm Staff and Planners


Nothing to disclose

All of the relevant financial relationships listed for these individuals have been mitigated.


This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

Disclosure of Unlabeled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

If you would like to opt out from future communications from AKH please send an email to with your information with "Opt Out" in the subject line.

AKH Privacy Policy (link:

Available Credit

  • 1.00 AMA PRA Category 1 Credit
  • 1.00 ANCC
  • 1.00 Participation
Please login or register to take this course.

Required Hardware/software

A computer with an internet connection

Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser

Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.